Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 21, 2023; 29(35): 5125-5137
Published online Sep 21, 2023. doi: 10.3748/wjg.v29.i35.5125
Published online Sep 21, 2023. doi: 10.3748/wjg.v29.i35.5125
Clinical characteristics and outcome of autoimmune pancreatitis based on serum immunoglobulin G4 level: A single-center, retrospective cohort study
Guan-Zhou Zhou, Jia-Qi Zeng, Ke Meng, Zi-Kai Wang, Xiu-Li Zhang, Li-Hua Peng, Bin Yan, Fei Pan, Department of Gastroenterology and Hepatology, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China
Guan-Zhou Zhou, School of Medicine, Nankai University, Tianjin 300071, China
Jia-Qi Zeng, Chinese PLA Medical School, Beijing 100853, China
Lei Wang, Department of Rheumatology, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China
Miao Liu, Department of Statistics and Epidemiology, Graduate School, Chinese PLA General Hospital, Beijing 100853, China
Author contributions: Pan F contributed to study conceptualization and reviewed the manuscript; Zhou GZ and Zeng JQ drafted the initial manuscript and reviewed the manuscript; Wang L and Liu M contributed to methodology and formal analysis; Zhou GZ, Yan B and Meng K contributed to data collection; Wang ZK, Zhang XL and Peng LH reviewed the manuscript; All authors approved the final manuscript as submitted, all authors had full access to the data in the present study and accept responsibility to submit for publication.
Supported by Young Scholar Independent Innovation Science Fund of Chinese PLA General Hospital , No. 22QNCZ020 ; National Key Research and Development Program , No. 2022YFC2504003 .
Institutional review board statement: The study was reviewed and approved for publication by our Institutional Reviewer.
Informed consent statement: As the study used anonymous and pre-existing data, the requirement for the informed consent from patients was waived.
Conflict-of-interest statement: All the Authors have no conflict of interest related to the manuscript.
Data sharing statement: The original anonymous dataset is available on request from the corresponding author at panfei@plagh.org.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Fei Pan, MD, PhD, Associate Chief Physician, Associate Professor, Department of Gastroenterology and Hepatology, The First Medical Center, Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing 100853, China. panfei@plagh.org
Received: May 22, 2023
Peer-review started: May 22, 2023
First decision: July 8, 2023
Revised: July 21, 2023
Accepted: September 1, 2023
Article in press: September 1, 2023
Published online: September 21, 2023
Processing time: 115 Days and 6.1 Hours
Peer-review started: May 22, 2023
First decision: July 8, 2023
Revised: July 21, 2023
Accepted: September 1, 2023
Article in press: September 1, 2023
Published online: September 21, 2023
Processing time: 115 Days and 6.1 Hours
Core Tip
Core tip: Our findings suggested that patients with a high immunoglobulin (Ig) G4 level had different clinical features including a more active immune system and higher relapse rate. Patients with normal IgG4 level still require attention because they have a high incidence of jaundice and pancreatic atrophy. Some factors were identified as risk factors for relapse, such as age > 55 years [hazard ratio (HR) 2.383; 95% confidence interval (CI) 1.056-5.378; P = 0.036], high IgG4 level [> 2 × upper limit of normal (ULN) (HR 3.583; 95%CI 1.218-10.545; P = 0.020) and high IgA level (> 1 × ULN) (HR 5.908; 95%CI 1.199-29.120; P = 0.029).